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Stereotactic body radiation therapy (SBRT) has rapidly been adopted into clinicalpractice as an option for patients with medically inoperable early-stage non-small cell
lung cancer (NSCLC) based on reports of excellent outcomes, often with local tumor
control 90%, from centers in North America, Europe, and Asia.1 Although data for
metastatic lung tumors are less robust, experience supporting SBRT as a viable alternative
to surgical resection in this patient population is growing, and Siva et al.2 provide a
comprehensive review of SBRT for pulmonary (oligo) metastases in this issue of the
journal. They conclude that SBRT seems both effective and safe in the metastatic setting
as a 2-year local tumor control approached 80%, whereas severe toxicity was observed in
less than 5% of patients.
Although several prospective single-arm SBRT trials have been conducted, the
recently reported results of the multicenter prospective Radiation Therapy Oncology
Group (RTOG) 0236 trial for early-stage NSCLC are nothing short of remarkable—
particularly for a treatment approach just starting to appear on the radar screen at the start
of this decade. Fifty-five high-risk patients with T1 or T2 N0 NSCLC were treated with
SBRT to a dose of 6000 cGy in three fractions of 2000 cGy (a 10-fold increase in the dose
per fraction given with conventionally fractionated radiotherapy).3 With intermediate-
term follow-up of 34.4 months (range 4.8–49.4 months), only one relapse in the primary
site was observed. Local tumor control in the involved lobe was 90.6% and estimated
3-year survival exceeded 50%. At the same time, treatment seemed tolerable with
protocol-specified grade 3 and grade 4 toxic events in 14% and 4% of patients,
respectively. It should be kept in mind in assessing these results that all patients had
FDG-PET imaging as a part of initial staging evaluation, only lesions located in the lung
periphery were treated, and institutions were required to undergo a rigorous quality
assurance process to participate.4 The treated population consisted predominantly of
women (62%) and T1 lesions (80%).
Although many reports suggest SBRT for early-stage NSCLC is associated with
limited toxicity, mature prospective results are just starting to appear in the literature.
Perhaps the most influential SBRT data come from a prospective phase II study performed
at Indiana University.5,6 This trial in essence served as the basis for RTOG 0236, but
unlike RTOG 0236 tumor location (e.g., central versus peripheral) was not a condition for
eligibility. An increased risk of toxic deaths after SBRT for centrally located lesions was
initially reported, although a statistically significant difference in severe toxicity was not
seen between central and peripheral lesions with longer follow-up. In addition to tumor
location, size of the gross tumor volume was a significant predictor of severe toxicity in
the Indiana University trial. In other experiences, pulmonary fatalities after SBRT have
been observed secondary to fistula (tracheoesophageal or bronchopulmonary), pneumo-
nitis, and hemoptysis, and tumor location as well as a history of prior radiotherapy and/or
Department of Radiation Oncology, Upstate Medical University, Syracuse, New York.
Disclosure: The author declares no conflicts of interest.
Address for correspondence: Jeffrey A. Bogart, MD, Department of Radiation Oncology, Upstate Medical University, Syracuse, NY 132310. E-mail:
bogartj@upstate.edu
Copyright © 2010 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/10/0507-0927
Journal of Thoracic Oncology • Volume 5, Number 7, July 2010 927
chemotherapy have been linked to toxicity.1 It should be
acknowledged that assigning a direct cause for pulmonary
toxicity in a population with baseline pulmonary dysfunction
is challenging at best, with some suggesting that aggravation
of dyspnea after SBRT reflects exacerbations of underlying
pulmonary disease rather than treatment-related toxicity.7
Moreover, fatal toxicity has also been observed after alterna-
tive treatment approaches for this population including sub-
lobar resection and radiofrequency ablation.8,9
Although the potential toxic effects of SBRT for cen-
trally located lesions have been emphasized, several recent
reports raise concerns about the treatment of very peripheral
lesions that may be in proximity to the rib and chest wall. In
this setting, unexpected high rates of skin, rib, and brachial
plexus toxicity after SBRT have now been reported even
from institutions with substantial SBRT experience and ex-
pertise.10–13 In fact, on the RTOG 0236 study, six patients
were classified as having adverse events that were not clas-
sified prospectively as protocol specified (as they were not
likely anticipated when the trial opened in 2004), including
three patients with grade 3 soft tissue (skin or rib) treatment-
related complications.3 Given these observations, specific
dose constraints for SBRT regimens have been updated by
the RTOG and the National Comprehensive Cancer Network
has published SBRT guidelines for NSCLC.14,15
In this issue of the journal, Devisetty and Salama16
report two cases of severe lung cavitation that developed
during the course of image-guided SBRT for peripheral
NSCLC. Although these changes were not associated with
clinical sequelae, the authors raised concerns given experi-
ence correlating cavitation with fatal bleeding in patients
receiving the antivascular endothelial growth factor receptor
bevacizumab with chemotherapy in advanced NCSLC.17 In-
terestingly, fatal toxicity (from fistula formation) has also
been reported after administration of bevacizumab in patients
with a history of thoracic radiotherapy.18 Although both
patients in this report had medical comorbidities including
vascular disease and diabetes mellitus, similar factors are
present in the majority of patients with stage I NSCLC
deemed ineligible for lobectomy. As such, it is not clear
which factors may have precipitated these unique radio-
graphic changes.
In fact, it is perhaps most surprising that there have
been relatively few reports of unusual and severe reactions
after the extreme doses delivered with SBRT. Although the
comfort level has risen with SBRT regimens, there is still
much to learn regarding the biology of very large radiother-
apy fractions and potential complications of therapy. As
opposed to conventionally fractionated radiotherapy, which
presumably follows classic radiobiologic principles predict-
ing preferential tumor cell killing and relative protection of
normal structures, SBRT uses doses that are theorized to have
a direct ablative effect on both tumors and surrounding tissue.
Therefore, the use of advanced technology such as (respira-
tory) motion management and image guidance are critical to
ensuring that radiation dose is applied only to the intended
target.
The development of SBRT for early-stage NSCLC is a
great success story for the field of radiation oncology in that
we can now offer patients a high-tech, noninvasive treatment
that can be completed in a minimum of visits with a high
expectation of success. For the most part, the question has
become: Which medically inoperable patients should not
receive SBRT? Nevertheless, there remains much work to be
done in identifying factors that place patients at high risk for
severe toxicity, and this may be particularly challenging
given marked variation in SBRT fractionation, dose, tech-
nique, target determination, and dose calculation algorithm.
And although outcomes for SBRT have been impres-
sive, alternative treatments options also seem quite promis-
ing. For example, single institution series have reported
excellent local tumor control after sublobar resection and
brachytherapy in high-risk T1N0 NSCLC, and the American
College of Surgeons Oncology Group recently completed a
phase III study assessing the addition of I-125 brachytherapy
to sublobar resection in this population.19 At this time, a
phase III trial comparing sublobar resection and SBRT is
being considered by the RTOG and American College of
Surgeons Oncology Group. Accelerated hypofractionated ra-
diation regimens that preserve some degree of fractionation
may also have merit. The Cancer and Leukemia Group B
recently reported mature results of accelerated conformal
radiotherapy to a dose of 70 Gy for node-negative NSCLC up
to 4 cm. With median follow-up of 53 months, only three
local failures were identified in 39 patients, whereas grade 3
toxic effects were observed in only two patients.20 An addi-
tional prospective trial from the NCI Canada testing a regi-
men of 60 Gy in 15 fractions more than 3 weeks for periph-
eral NSCLC lesions up to 5 cm completed accrual and results
should be reported in the near future.21
Advances in the past decade have radically changed
expectations for patients with medically inoperable early-
stage NSCLC. Phase III comparative studies will be neces-
sary to provide definitive information regarding the therapeu-
tic ratio of SBRT and alternative treatment options. In the
meantime, meticulous radiation treatment planning and de-
livery is essential for centers performing SBRT, and vigilance
is required in carefully monitoring and reporting patient
outcomes.
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